| | | 70193 | | 02.04.2026 | | Teva Pharma AG | | | | | | | 01.04.2031 | | | | | | 30000. | | | | 03.04.30. | | |
| | Seq.-No. | Product | Description | Galenic form | ATC-classification | |
|---|
| 01 | DuoResp Spiromax 160 ug / 4.5 ug | Pulver zur Inhalation | Inhalation Powder (Budesonide 160 µg, Formoteroli Fumaras Dihydricus 4.5 µg) | R03AK07 | | | 02 | DuoResp Spiromax 320 ug / 9 ug | Pulver zur Inhalation | Inhalation Powder (Budesonide 320 µg, Formoteroli Fumaras Dihydricus 9 µg) | R03AK07 | |
|
|
